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Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant
Recipients
To the Editor: Hepatitis C virus (HCV) infection continues to be the most frequent indication
for liver transplantation, but recurrence of infection is nearly universal in patients who are viremic at the time of transplantation.1 Direct-acting
antiviral agents (DAAs) have been shown to be
effective in treating recurrent HCV infection2,3
but have not been tested in preventing reinfection at the time of liver transplantation. Because HCV RNA levels fall precipitously after
liver transplantation owing to removal of the
liver, the immediate perioperative period before
rebound of viremia represents a unique opportunity to cure HCV infection.4 We hypothesized
that a DAA regimen shorter than the standard
12 to 24 weeks starting immediately before the
transplantation might prevent reinfection of the
new graft.
We conducted an open-label, multicenter, phase
2 study (ClinicalTrials.gov number, NCT02350569)
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involving wait-listed patients with chronic HCV
genotype 1 infection who were undergoing a first
liver transplantation from an HCV-negative donor.
Patients who had received previous DAA treatment or who had a creatinine clearance of less
than 40 ml per minute at the time of transplantation were excluded. A total of 37 patients were
screened, and 16 with a median unadjusted
Model for End-Stage Liver Disease score of 13
(on a scale from 6 to 40, with higher scores indicating more advanced liver disease) were enrolled (Fig. S1 and Table S1 in the Supplementary Appendix, available with the full text of this
letter at NEJM.org). Patients received a single dose
of ledipasvir (90 mg)–sofosbuvir (400 mg) the
day they arrived at the hospital for transplantation and once daily for 4 weeks postoperatively.
The primary efficacy end point was a sustained
virologic response 12 weeks after the end of the
4-week treatment. Deep sequencing of HCV NS5A
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Figure 1. Hepatitis C Virus (HCV) RNA Levels from Day –1 to Post-Treatment Week 12.
The black curves represent the patients who had a sustained virologic response 12 weeks after the end of the
4-week treatment. The green curve represents a patient who had a relapse after initial treatment and had a sustained virologic response after 12 weeks of retreatment. The orange curve represents a patient who discontinued
treatment on day 5 of the study owing to predefined stopping criteria. LLOQ denotes the lower limit of quantifi
cation.

and NS5B was performed for all recipients at
baseline.
Figure 1 shows HCV RNA levels from day −1
to the end of study. The rate of sustained virologic response for the 4-week course was 88%
(Table S2 in the Supplementary Appendix). One
patient had a relapse after the 4 weeks, but a
sustained virologic response was achieved after
retreatment with 12 weeks of ledipasvir–sofosbuvir per the study protocol, leading to an overall cure in 15 of the 16 patients (94%). This
patient had three NS5A resistance-associated
substitutions at study enrollment. One patient
discontinued treatment after the creatinine
clearance fell below a predefined threshold of
30 ml per minute on day 5. Overall, 88% of the
patients had adverse events after liver transplantation, and 31% had serious adverse events (Tables S3 and S4 in the Supplementary Appendix).
No patient discontinued treatment owing to an
adverse event, had graft loss, or died.
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In this trial of preemptive therapy in HCVpositive patients undergoing liver transplantation,
a 4-week course of perioperative ledipasvir–
sofosbuvir led to a high rate of sustained virologic response, suggesting that it may be an effective approach for preventing HCV recurrence.
The only patient with a virologic relapse had
NS5A resistance at baseline and had a response
to an additional 12 weeks of therapy, suggesting
that baseline resistance testing may guide the
need for standard courses of therapy. This new
perioperative approach needs to be tested in different populations, such as repeat or combined
organ recipients and patients with previous DAA
treatment failures, and in those with advanced
renal failure (other DAAs). In addition, there may
be an opportunity to test modifications of this
approach in liver or other solid organ recipients
being offered HCV-positive organs as a way to
increase the donor pool and number of transplants.

nejm.org

November 24, 2016

The New England Journal of Medicine
Downloaded from nejm.org at HENRY FORD HOSPITAL on December 17, 2019. For personal use only. No other uses without permission.
Copyright © 2016 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

Josh Levitsky, M.D.

of

m e dic i n e

3 weeks after publication of the article.
• Letters not related to a Journal article must not exceed 400
words.
• A letter can have no more than five references and one figure
or table.
• A letter can be signed by no more than three authors.
• Financial associations or other possible conflicts of interest
must be disclosed. Disclosures will be published with the
letters. (For authors of Journal articles who are responding
to letters, we will only publish new relevant relationships
that have developed since publication of the article.)
• Include your full mailing address, telephone number, fax
number, and e-mail address with your letter.
• All letters must be submitted at authors.NEJM.org.

Northwestern University
Chicago, IL
jlevitsk@nm.org

Elizabeth C. Verna, M.D.
Columbia University
New York, NY

Jacqueline G. O’Leary, M.D., M.P.H.
Baylor University
Dallas, TX

Natalie H. Bzowej, M.D.
Ochsner Clinical Foundation
New Orleans, LA

Dilip K. Moonka, M.D.

Letters that do not adhere to these instructions will not be
considered. We will notify you when we have made a decision
about possible publication. Letters regarding a recent Journal
article may be shared with the authors of that article. We are
unable to provide prepublication proofs. Submission of a
letter constitutes permission for the Massachusetts Medical
Society, its licensees, and its assignees to use it in the Journal’s
various print and electronic publications and in collections,
revisions, and any other form or medium.

Henry Ford Hospital
Detroit, MI

Robert H. Hyland, D.Phil.
Sarah Arterburn, M.S.
Hadas Dvory-Sobol, Ph.D.
Diana M. Brainard, M.D.
John G. McHutchison, M.D.
Gilead Sciences
Foster City, CA

notices

Norah A. Terrault, M.D., M.P.H.
University of California, San Francisco
San Francisco, CA
Supported by Gilead Sciences.
Disclosure forms provided by the authors are available with
the full text of this letter at NEJM.org.
1. Saxena V, Terrault N. Current management of hepatitis C
virus: regimens for peri-liver transplant patients. Clin Liver Dis
2015;19:669-88.
2. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med
2014;371:2375-82.
3. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and
sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:
649-59.
4. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus
kinetics during and immediately after liver transplantation.
Hepatology 2002;35:680-7.
DOI: 10.1056/NEJMc1611829
Correspondence Copyright © 2016 Massachusetts Medical Society.

instructions for letters to the editor

Letters to the Editor are considered for publication, subject
to editing and abridgment, provided they do not contain
material that has been submitted or published elsewhere.
Letters accepted for publication will appear in print, on our
website at NEJM.org, or both.
Please note the following:
• Letters in reference to a Journal article must not exceed 175
words (excluding references) and must be received within

n engl j med 375;21

Notices submitted for publication should contain a mailing
address and telephone number of a contact person or department. We regret that we are unable to publish all notices
received.
15TH ANNUAL MILD COGNITIVE IMPAIRMENT
SYMPOSIUM
The symposium, along with a workshop and public forum,
will be held in Miami Beach, FL, Jan. 14 and 15. It is presented
by the Wien Center for Alzheimer’s Disease and Memory Disorders, Mount Sinai Medical Center.
Contact MCI Symposium 2017, c/o World Events Forum,
1631 Whitcomb Ave., Des Plaines, IL 60018; or call (224) 9389523; or e-mail meetings@worldeventsforum.com; or see http://
www.mcisymposium.org.

10TH INTERNATIONAL CONFERENCE ON ACUTE
CARDIAC CARE
The conference will be held in Tel Aviv, Israel, Jan. 15–17.
Contact the Secretariat, 10th International Conference –
ACC2017, P.O. Box 574, Jerusalem 91004, Israel; or call 972-26520574; or fax 972-2-6520558; or e-mail seminars@isas.co.il;
or see http://www.acute-cardiac-care.com.

11TH ANNUAL DRUG DISCOVERY FOR
NEURODEGENERATION CONFERENCE
The conference will be held in San Diego, CA, Feb. 12–14. It
is presented by the Alzheimer’s Drug Discovery Foundation.
Contact Sara Classen, Scientific Events, Alzheimer’s Drug
Discovery Foundation, 57 W. 57th St., Suite 904, New York, NY
10019; or call (212) 901-8009; or fax (212) 901-8010; or e-mail
sclassen@alzdiscovery.org; or see http://worldeventsforum.com/
addf/drugdiscovery.
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